Inflammatory bowel diseases (IBDs) are chronic and relapsing disorders that affect the quality of life in many individuals around the world. Over the past few years, the prevalence of IBDs is substantially rising which might pose a considerable social and economic burden on health systems. Progresses in the management of chronic inflammatory diseases lead to prolonged remission phase and decreased hospitalization rate. However, during treatment, many patients become refractory to conventional therapies. Recently, advanced approaches using somatic cell therapy medicinal products (SCTMPs) including immune and stem cell-based therapies have drawn many researchers’ attentions. Promising results from recent trials, alongside with the emerging market indicated that these therapeutic approaches could be an alternative and promising treatment to conventional therapies. In this review, we will discuss recent advances in cell-based therapies, which have been developed for treatment of IBDs. In addition, the global emerging market and the novel products in this field are highlighted.

炎症性肠病 (IBD) 是慢性和复发性疾病，影响世界各地许多人的生活质量。在过去几年中，IBD 的患病率大幅上升，这可能对卫生系统造成相当大的社会和经济负担。慢性炎症性疾病管理的进展导致缓解期延长和住院率降低。然而，在治疗过程中，许多患者对常规疗法难以治疗。最近，使用包括免疫和干细胞疗法在内的体细胞治疗药物 (SCTMP) 的先进方法引起了许多研究人员的关注。最近试验的有希望的结果，与新兴市场一起表明，这些治疗方法可能是传统疗法的替代疗法和有前途的疗法。在这篇综述中，我们将讨论为治疗 IBD 而开发的细胞疗法的最新进展。此外，重点介绍了全球新兴市场和该领域的新产品。